Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J Perkins

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Australian and New Zealand Journal of Surgery|September 16, 1998
A preliminary exploration of the interactional skills of trainee surgeonsJ J Perkins, R W Sanson-Fisher, P Anseline, et al.
Medical Education|July 1, 1991
Training medical practitioners in information transfer skills: the new challengeR W Sanson-Fisher, S Redman, R Walsh, et al.
Addiction (Abingdon, England)|October 1, 1994
The prevalence of drug use in urban aboriginal communitiesJ J Perkins, R W Sanson-Fisher, S Blunden, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 4, 1998
Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptorsT E Johnson, M K Holloway, R Vogel, et al.
Journal of Medicinal Chemistry|August 18, 1995
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonistM E Duggan, A M Naylor-Olsen, J J Perkins, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 1999
Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitorsG D Hartman, M E Duggan, W F Hoffman, et al.
Journal of Medicinal Chemistry|October 6, 2000
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonistM E Duggan, L T Duong, J E Fisher, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1996
Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217J J Cook, M A Holahan, E A Lyle, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Australian and New Zealand Journal of Surgery|September 16, 1998
A preliminary exploration of the interactional skills of trainee surgeonsJ J Perkins, R W Sanson-Fisher, P Anseline, et al.
Medical Education|July 1, 1991
Training medical practitioners in information transfer skills: the new challengeR W Sanson-Fisher, S Redman, R Walsh, et al.
Addiction (Abingdon, England)|October 1, 1994
The prevalence of drug use in urban aboriginal communitiesJ J Perkins, R W Sanson-Fisher, S Blunden, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 4, 1998
Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptorsT E Johnson, M K Holloway, R Vogel, et al.
Journal of Medicinal Chemistry|August 18, 1995
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonistM E Duggan, A M Naylor-Olsen, J J Perkins, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 1999
Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitorsG D Hartman, M E Duggan, W F Hoffman, et al.
Journal of Medicinal Chemistry|October 6, 2000
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonistM E Duggan, L T Duong, J E Fisher, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1996
Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217J J Cook, M A Holahan, E A Lyle, et al.
Pageof 2